Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05819528 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Primary Cardiac Lymphoma: Italian Multicenter Experience

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Apr 2026 → Oct 2026
See other at-risk trials from Fondazione Italiana Linfomi - ETS

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Apr 2026 to Oct 2026
    • Trial sites reduced: 17 → 13 locations
    • Study completion pushed from Jun 2026 to Oct 2026
    v8
  2. Site details revised at 2 of 17 sitesv7
  3. Site details revised at 5 of 17 sitesv6
  4. Primary completion date: Mar 2025 to Apr 2026
    • Study sites: 19 to 17
    • Study completion date: Mar 2025 to Jun 2026
    • Start date changed from estimate of Sep 2024 to Oct 2, 2024
    v5
  5. Trial status: Not Yet Recruiting to Recruitingv4 Show 5 more changesShow less
    • Primary completion date: Dec 31, 2023 to Mar 2025
    • Start date: Sep 1, 2023 to Sep 2024
    • Study completion date: Feb 29, 2024 to Mar 2025
    • Eligibility criteria expanded, about 15 words
    • Site details revised at 19 of 19 sites
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: May 1, 2023 to Sep 1, 2023v3
  2. Secondary endpoints: details revised at 1 of 7 entriesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The rationale of this study is to provide an overview on PCL (Primary Cardiac Lymphoma) in Italy, trying to shed light on unknown aspects of the disease and on unanswered questions about its management that could be helpful in clinical practice.
Trial Details
NCT Number NCT05819528
Lead Sponsor Fondazione Italiana Linfomi - ETS
Conditions
(from sponsor)		 Primary Cardiac Lymphoma
Enrollment 43 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov